- Home
- SRTS vs PDSB Comparison
SRTS vs PDSB Comparison
Compare SRTS & PDSB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRTS
- PDSB
- Stock Information
- Founded
- SRTS 2010
- PDSB 2005
- Country
- SRTS United States
- PDSB United States
- Employees
- SRTS N/A
- PDSB N/A
- Industry
- SRTS Medical/Dental Instruments
- PDSB Biotechnology: Pharmaceutical Preparations
- Sector
- SRTS Health Care
- PDSB Health Care
- Exchange
- SRTS Nasdaq
- PDSB Nasdaq
- Market Cap
- SRTS 75.5M
- PDSB 72.2M
- IPO Year
- SRTS 2016
- PDSB N/A
- Fundamental
- Price
- SRTS $5.33
- PDSB $1.12
- Analyst Decision
- SRTS Strong Buy
- PDSB Strong Buy
- Analyst Count
- SRTS 3
- PDSB 2
- Target Price
- SRTS $11.67
- PDSB $10.00
- AVG Volume (30 Days)
- SRTS 134.3K
- PDSB 433.5K
- Earning Date
- SRTS 08-07-2025
- PDSB 08-13-2025
- Dividend Yield
- SRTS N/A
- PDSB N/A
- EPS Growth
- SRTS N/A
- PDSB N/A
- EPS
- SRTS 0.11
- PDSB N/A
- Revenue
- SRTS $39,488,000.00
- PDSB N/A
- Revenue This Year
- SRTS $4.33
- PDSB N/A
- Revenue Next Year
- SRTS $26.74
- PDSB N/A
- P/E Ratio
- SRTS $47.72
- PDSB N/A
- Revenue Growth
- SRTS 24.75
- PDSB N/A
- 52 Week Low
- SRTS $4.01
- PDSB $0.85
- 52 Week High
- SRTS $9.33
- PDSB $4.29
- Technical
- Relative Strength Index (RSI)
- SRTS 57.88
- PDSB 40.60
- Support Level
- SRTS $5.21
- PDSB $1.02
- Resistance Level
- SRTS $5.92
- PDSB $1.27
- Average True Range (ATR)
- SRTS 0.39
- PDSB 0.09
- MACD
- SRTS 0.04
- PDSB 0.00
- Stochastic Oscillator
- SRTS 63.80
- PDSB 42.31
About SRTS Sensus Healthcare Inc.
Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating both oncological and non-oncological skin conditions including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated majorly from customers in the United States.
About PDSB PDS Biotechnology Corporation
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.